Clinical Trial Update: A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab [Phase 4]

View source ↗

Summary

Phase 4 multicenter study results evaluating immune response to influenza vaccination in adults with relapsing multiple sclerosis treated with ofatumumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis | Phase 4 | Status: COMPLETED | Results posted: 2024-08-01